GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TME Pharma NV (XPAR:ALTME) » Definitions » Price-to-Owner-Earnings

TME Pharma NV (XPAR:ALTME) Price-to-Owner-Earnings : (As of May. 31, 2024)


View and export this data going back to 2016. Start your Free Trial

What is TME Pharma NV Price-to-Owner-Earnings?

As of today (2024-05-31), TME Pharma NV's share price is €0.2495. TME Pharma NV does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for TME Pharma NV's Price-to-Owner-Earnings or its related term are showing as below:


XPAR:ALTME's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 32.61
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-31), TME Pharma NV's share price is €0.2495. TME Pharma NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-1.34. Therefore, TME Pharma NV's PE Ratio for today is At Loss.

As of today (2024-05-31), TME Pharma NV's share price is €0.2495. TME Pharma NV's EPS without NRI for the trailing twelve months (TTM) ended in was €-1.34. Therefore, TME Pharma NV's PE Ratio without NRI for today is At Loss.


TME Pharma NV Price-to-Owner-Earnings Historical Data

The historical data trend for TME Pharma NV's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TME Pharma NV Price-to-Owner-Earnings Chart

TME Pharma NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

TME Pharma NV Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of TME Pharma NV's Price-to-Owner-Earnings

For the Biotechnology subindustry, TME Pharma NV's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TME Pharma NV's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TME Pharma NV's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where TME Pharma NV's Price-to-Owner-Earnings falls into.



TME Pharma NV Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

TME Pharma NV's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.2495/-1.43
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TME Pharma NV  (XPAR:ALTME) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


TME Pharma NV Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of TME Pharma NV's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


TME Pharma NV (XPAR:ALTME) Business Description

Traded in Other Exchanges
Address
Max-Dohrn-Street 8-10, Berlin, DEU, 10589
TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product candidates are; NOX-A12 and NOX-E36 are based on a new class of drug first developed by TME Pharma called Spiegelmers, which offer specific advantages over other drug classes.

TME Pharma NV (XPAR:ALTME) Headlines

No Headlines